ArticleFrontiers in cellular and infection microbiology2021
Latent Cytomegalovirus Reactivation in Patients With Liver Failure: A 10-Year Retrospective Case-Control Study, 2011-2020.
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 29 citations in OpenAlex.
- Higher prevalence of cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure.JHEP reports : innovation in hepatology · 2026Article
- Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on "Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation".Clinical and molecular hepatology · 2026Article
- mNGS improves the efficiency of infection diagnosis and treatment in acute-on-chronic liver failure.BMC gastroenterology · 2026Observational
- Application of Droplet Digital PCR in Sputum Samples in Myasthenia Gravis Patients with Pneumonia.Infection and drug resistance · 2026Article
- DPMAS in the Management of Severe Acute Liver Injury.Case reports in hepatology · 2026Article
- Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation.Clinical and molecular hepatology · 2025Observational
- Iodine-131 Combined With Plasma Exchange Treatment in Graves' Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20.Gastro hep advances · 2025Article
- Liver failure as the initial presentation in cancer of unknown primary: a case report.BMC infectious diseases · 2023Article
- Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to explore potential risk factors for cytomegalovirus (CMV) reactivation and their impact on liver failure patient outcomes. Methods: A 10-year retrospective case-control study was conducted in adult participants, who were diagnosed with liver failure and had undergone CMV DNA tests. CMV reactivation cases were matched with controls at a 2:1 ratio based on age, sex, and year of admission. Univariate and multivariate analyses were used to explore risk factors for CMV reactivation. Results: Between January 2011 and April 2020, 198 adult patients with liver failure and available CMV DNA test results were enrolled into the study. Among them, 33 patients had detectable CMV DNA in their plasma (16.7%). Clinical manifestations and liver function were comparable between the CMV reactivation and non-reactivation groups. However, CMV reactivation may triple mortality in patients with liver failure. We found that nearly 50% of patients in the CMV-positive group received glucocorticoids, compared to 13.6% in the CMV-negative group ( Conclusions: High intravenous glucocorticoid doses may be the most important risk factor for CMV reactivation in liver failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.